1
|
Ambrosini F, Pose R, Tilki D, Chun F, Steuber T, Salomon G, Michl U, Heinzer H, Maurer T, Isbarn H, Budäus L, Huland H, Terrone C, Tennstedt P, Graefen M, Haese A. Nerve-Sparing Radical Prostatectomy (NSRP) using the NeuroSAFE technique is oncologically safe: Results after 20 years of experience. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00530-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
Pose R, Knipper S, Hohenhorst L, Beyer B, Haese A, Heinzer H, Salomon G, Steuber T, Budäus L, Tilki D, Isbarn H, Maurer T, Tennstedt P, Graefen M, Michl U. Impact of peritoneal bladder flap on the risk of lymphoceles after robotic radical prostatectomy: Results of a prospective controlled trial. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00703-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
3
|
Salomon G, Sturm N. Results of the requirement analysis as part of the Austrian research project linked care. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Sufficient information is the foundation for efficient and high-quality health care services. In the field of extramural health care, this challenge is particularly evident: missing or insufficient information can lead to underuse, overuse, or misuse of health care, e.g. due to the necessity of multiple assessments or lack of relevant information. The noticeable shortage of health care professionals further underscores the urgent need for efficient and quality-assured health care services. The aim of the project LICA - linked care - is to provide a platform for better coordination and information exchange between health professionals involved in home care, with a focus on ICT in nursing in Austria. The project is funded by the Austrian Research Promotion agency (FFG) as part of the “benefit - demografischer Wandel als Chance” program (April 2020-March 2025). The requirement analysis was conducted from April to December 2021. In light of the user-centered approach a mix of methods was chosen, consisting of: literature analysis, 5 guideline-based focus group interviews, guideline-based expert interviews n = 44 (people in need of care n = 23, health professionals n = 21), documentation-analysis (4 care documentation systems - from participating project partners) and working diaries: n = 5 on 5 consecutive working days (=25 diaries). Therefore, three main target groups were identified: i) people in need of care, ii) healthcare professionals and iii) healthcare providers. The data were analyzed using a qualitative content analysis based on Kuckartz. The main results regarding the status quo are: i) different documentation systems are utilized, ii) lack of digitized documents, iii) currently no standardized documentation system is in use. Thus, following requirements could be identified: i) interoperability with existing systems, ii) setting comprehensive function, iii) usability, iv) interdisciplinary readability, v) error-management, and vi) proper data protection measures.
Key messages
• Healthcare systems are under great pressure worldwide. Innovative solutions can help maintain and improve the quality and efficacy of healthcare services.
• Gapless and efficient information provision is a key essential to high quality healthcare. The project offers a user-centric approach to develop a platform for connectivity of existing systems.
Collapse
Affiliation(s)
- G Salomon
- Johanniter Ausbildung und Forschung gem. GmbH Research, , Vienna, Austria
| | - N Sturm
- Johanniter Ausbildung und Forschung gem. GmbH Research, , Vienna, Austria
| |
Collapse
|
4
|
Preisser F, Pose R, Heinze A, Steuber T, Michl U, Salomon G, Chun F, Graefen M, Tilki D, Michl. Impact of persistent PSA in salvage radical prostatectomy patients for recurrent prostate cancer. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00270-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Salomon G, Severino M, Casassa E, Livideanu CB, Meyer N, Lamant L, Tournier E, Paul C. Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study. Ann Dermatol Venereol 2022; 149:139-141. [PMID: 35115205 DOI: 10.1016/j.annder.2021.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 07/21/2021] [Accepted: 12/22/2021] [Indexed: 11/19/2022]
Affiliation(s)
- G Salomon
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France.
| | - M Severino
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| | - E Casassa
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| | - C Bulai Livideanu
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| | - N Meyer
- Onco-Dermatology, University Institute of Cancer, University Hospital, 31100 Toulouse, France
| | - L Lamant
- Pathology, University Institute of Cancer, University Hospital, 31100 Toulouse, France
| | - E Tournier
- Pathology, University Institute of Cancer, University Hospital, 31100 Toulouse, France
| | - C Paul
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| |
Collapse
|
6
|
Carmignac V, Salomon G, Severino-Freire M, Duffourd Y, Chevarin M, Vabres P, Mazereeuw-Hautier J. Mosaic NEK9 mutation, fibrous dysplasia and premature puberty in naevus comedonicus syndrome. Br J Dermatol 2021; 185:1247-1249. [PMID: 34184242 DOI: 10.1111/bjd.20603] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 06/09/2021] [Accepted: 06/26/2021] [Indexed: 11/30/2022]
Affiliation(s)
- V Carmignac
- Centre de référence MAGEC-Mosaïque, Dermatologie - CHU Dijon, Dijon, France.,Equipe GAD - UF 6254 CHU Dijon - INSERM UMR1231, Dijon, France
| | - G Salomon
- Dermatologie, Centre de Référence des Maladies Rares de la Peau, Toulouse, France
| | - M Severino-Freire
- Dermatologie, Centre de Référence des Maladies Rares de la Peau, Toulouse, France
| | - Y Duffourd
- Equipe GAD - UF 6254 CHU Dijon - INSERM UMR1231, Dijon, France
| | - M Chevarin
- Equipe GAD - UF 6254 CHU Dijon - INSERM UMR1231, Dijon, France
| | - P Vabres
- Centre de référence MAGEC-Mosaïque, Dermatologie - CHU Dijon, Dijon, France.,Equipe GAD - UF 6254 CHU Dijon - INSERM UMR1231, Dijon, France
| | - J Mazereeuw-Hautier
- Dermatologie, Centre de Référence des Maladies Rares de la Peau, Toulouse, France
| |
Collapse
|
7
|
Preisser F, Pose R, Heinze A, Steuber T, Michl U, Salomon G, Chun F, Graefen M, Tilki D. Validation of EAU recommendation for salvage radical prostatectomy candidates. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01564-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Wildeboer RR, van Sloun RJG, Mannaerts CK, Moraes PH, Salomon G, Chammas MC, Wijkstra H, Mischi M. Synthetic Elastography Using B-Mode Ultrasound Through a Deep Fully Convolutional Neural Network. IEEE Trans Ultrason Ferroelectr Freq Control 2020; 67:2640-2648. [PMID: 32217475 DOI: 10.1109/tuffc.2020.2983099] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Shear-wave elastography (SWE) permits local estimation of tissue elasticity, an important imaging marker in biomedicine. This recently developed, advanced technique assesses the speed of a laterally traveling shear wave after an acoustic radiation force "push" to estimate local Young's moduli in an operator-independent fashion. In this work, we show how synthetic SWE (sSWE) images can be generated based on conventional B-mode imaging through deep learning. Using side-by-side-view B-mode/SWE images collected in 50 patients with prostate cancer, we show that sSWE images with a pixel-wise mean absolute error of 4.5 ± 0.96 kPa with regard to the original SWE can be generated. Visualization of high-level feature levels through t -distributed stochastic neighbor embedding reveals substantial overlap between data from two different scanners. Qualitatively, we examined the use of the sSWE methodology for B-mode images obtained with a scanner without SWE functionality. We also examined the use of this type of network in elasticity imaging in the thyroid. Limitations of the technique reside in the fact that networks have to be retrained for different organs, and that the method requires standardization of the imaging settings and procedure. Future research will be aimed at the development of sSWE as an elasticity-related tissue typing strategy that is solely based on B-mode ultrasound acquisition, and the examination of its clinical utility.
Collapse
|
9
|
Rudenko V, Serova N, Kapanadze L, Taratkin M, Okhunov Z, Ritter M, Kriegmair M, Kozlov V, Laukhtina E, Aleksandrova K, Salomon G, Enikeev D, Glybochko P. Dual-energy computed tomography for stone type assessment: A pilot study of DECT with five indices. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)36083-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Wildeboer RR, Sammali F, van Sloun RJG, Huang Y, Chen P, Bruce M, Rabotti C, Shulepov S, Salomon G, Schoot BC, Wijkstra H, Mischi M. Blind Source Separation for Clutter and Noise Suppression in Ultrasound Imaging: Review for Different Applications. IEEE Trans Ultrason Ferroelectr Freq Control 2020; 67:1497-1512. [PMID: 32091998 DOI: 10.1109/tuffc.2020.2975483] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Blind source separation (BSS) refers to a number of signal processing techniques that decompose a signal into several "source" signals. In recent years, BSS is increasingly employed for the suppression of clutter and noise in ultrasonic imaging. In particular, its ability to separate sources based on measures of independence rather than their temporal or spatial frequency content makes BSS a powerful filtering tool for data in which the desired and undesired signals overlap in the spectral domain. The purpose of this work was to review the existing BSS methods and their potential in ultrasound imaging. Furthermore, we tested and compared the effectiveness of these techniques in the field of contrast-ultrasound super-resolution, contrast quantification, and speckle tracking. For all applications, this was done in silico, in vitro, and in vivo. We found that the critical step in BSS filtering is the identification of components containing the desired signal and highlighted the value of a priori domain knowledge to define effective criteria for signal component selection.
Collapse
|
11
|
Pompe R, Preisser F, Gild P, Mandel P, Leyh-Bannurah S, Salomon G, Graefen M, Huland H, Fisch M, Tilki D. Early urinary continence a reliable marker for further functional outcomes. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34034-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Pompe R, Wiegel T, Bartkowiak D, Preisser F, Leyh-Bannurah S, Gild P, Salomon G, Graefen M, Siegmann A, Böhmer D, Budach V, Fisch M, Huland H, Tilki D. EAU BCR risk classification as decision tool for salvage radiatiotherapy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33532-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Michl U, Haese A, Heinzer H, Salomon G, Steuber T, Budäus L, Tilki D, Isbarn H, Maurer T, Tennstedt P, Graefen M. Halving the risk of symptomatic lymphoceles after radical prostatectomy: Results of a randomised-controlled study including 1080 patients. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33707-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
14
|
Pompe R, Preisser F, Leyh-Bannurah S, Gild P, Salomon G, Graefen M, Fisch M, Huland H, Tilki D. Association of very low PSA with increased metastases and death in patients with biopsy Gleason score 8-10 prostate cancer. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33874-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
15
|
Pfalzgraf D, Worst T, Kranz J, Steffens J, Salomon G, Fisch M, Reiß CP, Vetterlein MW, Rosenbaum CM. Vesico-urethral anastomotic stenosis following radical prostatectomy: a multi-institutional outcome analysis with a focus on endoscopic approach, surgical sequence, and the impact of radiation therapy. World J Urol 2020; 39:89-95. [PMID: 32236662 DOI: 10.1007/s00345-020-03157-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Accepted: 03/03/2020] [Indexed: 12/01/2022] Open
Abstract
OBJECTIVES To investigate the predictors of recurrence and of de novo incontinence in patients treated by transurethral incision or resection for vesico-urethral anastomotic stenosis (VUAS) after radical prostatectomy. MATERIAL AND METHODS All patients undergoing endoscopic treatment for VUAS between March 2009 and October 2016 were identified in our multi-institutional database. Digital chart reviews were performed and patients contacted for follow-up. Recurrence was defined as any need for further instrumentation or surgery, and de-novo-incontinence as patient-reported outcome. RESULTS Of 103 patients undergoing endoscopic VUAS treatment, 67 (65%) underwent transurethral resection (TR) and 36 (35%) transurethral incision (TI). TI was performed more frequently as primary treatment compared to TR (58% vs. 37%; p = 0.041). Primary and repeated treatment was performed in 46 (45%) and 57 patients (55%), respectively. Overall, 38 patients (37%) had a history of radiation therapy. There was no difference in time to recurrence for primary vs repeat VUAS treatment, previous vs no radiation, TR compared to TI (all p > 0.08). Regarding treatment success, no difference was found for primary vs. repeat VUAS treatment (50% vs. 37%), previous radiation vs. no radiation (42% vs. 43%), and TR vs. TI (37% vs. 53%; all p ≥ 0.1). Postoperative de novo incontinence was more common after TI vs. TR (31% vs. 12%; p = 0.032), no difference was observed for previous radiation therapy vs. no radiation therapy (18% vs. 18%; p > 0.9) or primary vs. repeat VUAS treatment (22% vs. 16%; p = 0.5). CONCLUSION VUAS recurrence after endoscopic treatment is not predictable. Endoscopic treatment with TI showed a higher risk for de novo incontinence than TR, and previous irradiation and the number of treatments do not influence incontinence.
Collapse
Affiliation(s)
- D Pfalzgraf
- Heilig-Geist-Hospital, Bensheim, Germany. .,University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
| | - T Worst
- University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany
| | - J Kranz
- St.-Antonius-Hospital, Eschweiler, Germany.,University Medical Centre Halle, Halle, Germany
| | - J Steffens
- St.-Antonius-Hospital, Eschweiler, Germany
| | - G Salomon
- Martini-Clinic, Prostate Cancer Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - M Fisch
- University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - C P Reiß
- University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - M W Vetterlein
- University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - C M Rosenbaum
- University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.,Asklepios Clinic Hamburg Barmbek, Barmbek, Germany
| |
Collapse
|
16
|
Benzebouchi N, Salomon G, Maza A, Mazereeuw-Hautier J. Calcinose cutanée idiopathique de type milium (3 cas). Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Salomon G, Severino M, Casassa E, Bulai Livideanu C, Meyer N, Lamant L, Tournier E, Paul C. Les manifestations cutanées du syndrome hyperéosinophilique sont polymorphes et difficiles à traiter : étude de cohorte rétrospective. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.481] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Schostak M, Wendler JJ, Baumunk D, Blana A, Ganzer R, Franiel T, Hadaschik B, Henkel T, Köhrmann KU, Köllermann J, Kuru T, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Witzsch U, Liehr UB. Treatment of Small Renal Masses. Urol Oncol 2019. [DOI: 10.1007/978-3-319-42623-5_61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Salomon G, Giordano-Labadie F. Allergie aux acrylates et électrodes : un frein à une prise en charge médicale optimale ? Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Salomon G, Giordano-Labadie F. Éviction de la méthylisothiazolinone : pas facile en pratique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Salomon G. Partielle Drüsenablation mit vaskulär gezielter Phototherapie vs. aktive Überwachung beim Niedrigrisikoprostatakarzinom. Urologe A 2018; 57:1496-1498. [DOI: 10.1007/s00120-018-0809-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Salomon G, Maza A, Boulinguez S, Paul C, Lamant L, Tournier E, Mazereeuw-Hautier J, Meyer N. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol 2018; 178:1199-1203. [PMID: 29274233 DOI: 10.1111/bjd.16270] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/15/2017] [Indexed: 12/27/2022]
Abstract
Xeroderma pigmentosum (XP) is an orphan disease of poor prognosis. We report one case of parallel efficacy with anti-programmed cell death-1 (PD-1) antibody on both melanoma and skin carcinoma in a patient with XP. A 17-year-old patient presented with metastatic melanoma and multiple nonmelanoma skin cancers. He was treated with pembrolizumab, a monoclonal anti-PD-1 antibody, at a dose of 2 mg kg-1 , every 3 weeks. Parallel therapeutic efficacy of anti-PD-1 was observed in metastatic melanoma and skin carcinomas, and maintained at week 24. This observation suggests anti-PD-1 may be considered in patients with XP and metastatic melanoma in addition to advanced nonmelanoma skin cancer.
Collapse
Affiliation(s)
- G Salomon
- Dermatology, Paul Sabatier-Toulouse III University, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,CHU de Toulouse, Larrey Hospital, Toulouse, France
| | - A Maza
- Dermatology, Paul Sabatier-Toulouse III University, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,CHU de Toulouse, Larrey Hospital, Toulouse, France.,Reference Center for Rare Skin Diseases, Toulouse, France
| | - S Boulinguez
- Dermatology, Paul Sabatier-Toulouse III University, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,CHU de Toulouse, Larrey Hospital, Toulouse, France
| | - C Paul
- Dermatology, Paul Sabatier-Toulouse III University, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,CHU de Toulouse, Larrey Hospital, Toulouse, France
| | - L Lamant
- Pathology, University Cancer Institute of Toulouse, Toulouse, France
| | - E Tournier
- Pathology, University Cancer Institute of Toulouse, Toulouse, France
| | - J Mazereeuw-Hautier
- Dermatology, Paul Sabatier-Toulouse III University, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,CHU de Toulouse, Larrey Hospital, Toulouse, France.,Reference Center for Rare Skin Diseases, Toulouse, France
| | - N Meyer
- Dermatology, Paul Sabatier-Toulouse III University, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,CHU de Toulouse, Larrey Hospital, Toulouse, France
| |
Collapse
|
23
|
Schostak M, Wendler JJ, Baumunk D, Blana A, Ganzer R, Franiel T, Hadaschik B, Henkel T, Köhrmann KU, Köllermann J, Kuru T, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Witzsch U, Liehr UB. Treatment of Small Renal Masses. Urol Oncol 2018. [DOI: 10.1007/978-3-319-42603-7_61-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Salomon G, Riffaud L, Boulinguez S, Sibaud V, Meyer N. Porokératose actinique résolutive sous immunothérapie : à propos d’un cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Franz T, von Hardenberg J, Blana A, Cash H, Baumunk D, Salomon G, Hadaschik B, Henkel T, Herrmann J, Kahmann F, Köhrmann KU, Köllermann J, Kruck S, Liehr UB, Machtens S, Peters I, Radtke JP, Roosen A, Schlemmer HP, Sentker L, Wendler JJ, Witzsch U, Stolzenburg JU, Schostak M, Ganzer R. [MRI/TRUS fusion-guided prostate biopsy : Value in the context of focal therapy]. Urologe A 2017; 56:208-216. [PMID: 27844131 DOI: 10.1007/s00120-016-0268-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Several systems for MRI/TRUS fusion-guided biopsy of the prostate are commercially available. Many studies have shown superiority of fusion systems for tumor detection and diagnostic quality compared to random biopsy. The benefit of fusion systems in focal therapy of prostate cancer (PC) is less clear. OBJECTIVES Critical considerations of fusion systems for planning and monitoring of focal therapy of PC were investigated. MATERIALS AND METHODS A systematic literature review of available fusion systems for the period 2013-5/2016 was performed. A checklist of technical details, suitability for special anatomic situations and suitability for focal therapy was established by the German working group for focal therapy (Arbeitskreis fokale und Mikrotherapie). RESULTS Eight fusion systems were considered (Artemis™, BioJet, BiopSee®, iSR´obot™ Mona Lisa, Hitachi HI-RVS, UroNav and Urostation®). Differences were found for biopsy mode (transrectal, perineal, both), fusion mode (elastic or rigid), navigation (image-based, electromagnetic sensor-based or mechanical sensor-based) and space requirements. DISCUSSION Several consensus groups recommend fusion systems for focal therapy. Useful features are "needle tracking" and compatibility between fusion system and treatment device (available for Artemis™, BiopSee® and Urostation® with Focal One®; BiopSee®, Hitachi HI-RVS with NanoKnife®; BioJet, BiopSee® with cryoablation, brachytherapy). CONCLUSIONS There are a few studies for treatment planning. However, studies on treatment monitoring after focal therapy are missing.
Collapse
Affiliation(s)
- T Franz
- Klinik und Poliklinik für Urologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 04103, Leipzig, Deutschland
| | - J von Hardenberg
- Klinik für Urologie, Universitätsmedizin Mannheim der Universität Heidelberg, Mannheim, Deutschland
| | - A Blana
- Klinik für Urologie und Kinderurologie, Klinikum Fürth, Fürth, Deutschland
| | - H Cash
- Klinik für Urologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland
| | - D Baumunk
- Universitätsklinik für Urologie und Kinderurologie, Universität Magdeburg, Magdeburg, Deutschland
| | - G Salomon
- Martini-Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
| | - B Hadaschik
- Urologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - T Henkel
- Praxis Urologie Britz, Berlin, Deutschland
| | - J Herrmann
- Klinik für Urologie, Universitätsmedizin Mannheim der Universität Heidelberg, Mannheim, Deutschland
| | - F Kahmann
- Praxis Urologie Britz, Berlin, Deutschland
| | - K-U Köhrmann
- Abteilung für Urologie, Theresienkrankenhaus Mannheim, Mannheim, Deutschland
| | - J Köllermann
- Institut für Pathologie, Sana Klinikum Offenbach, Offenbach, Deutschland
| | - S Kruck
- Klinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - U-B Liehr
- Universitätsklinik für Urologie und Kinderurologie, Universität Magdeburg, Magdeburg, Deutschland
| | - S Machtens
- Klinik für Urologie, Marien-Krankenhaus, Bergisch Gladbach, Deutschland
| | - I Peters
- Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - J P Radtke
- Urologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - A Roosen
- Klinik für Urologie, Augusta-Kranken-Anstalt GmbH, Bochum, Deutschland
| | - H-P Schlemmer
- Abteilung für Radiologie, Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Deutschland
| | - L Sentker
- Zentrum f. Urologie Sinsheim/Walldorf/Wiesloch, Sinsheim, Deutschland
| | - J J Wendler
- Universitätsklinik für Urologie und Kinderurologie, Universität Magdeburg, Magdeburg, Deutschland
| | - U Witzsch
- Klinik für Urologie und Kinderurologie, Klinikum Nordwest, Frankfurt am Main, Deutschland
| | - J-U Stolzenburg
- Klinik und Poliklinik für Urologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 04103, Leipzig, Deutschland
| | - M Schostak
- Universitätsklinik für Urologie und Kinderurologie, Universität Magdeburg, Magdeburg, Deutschland
| | - R Ganzer
- Klinik und Poliklinik für Urologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 04103, Leipzig, Deutschland.
| |
Collapse
|
26
|
Sauer M, Strölin P, Salomon G, Budäus L, Adam G, Beyersdorff D. Wert der multiparametrischen Prostata MRT bei Patienten mit Gleason 3+3 Stanzbiopsie unter Active Surveillance oder vor radikaler Prostatektomie. ROFO-FORTSCHR RONTG 2017. [DOI: 10.1055/s-0037-1600471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- M Sauer
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| | - P Strölin
- Martini Klinik, Universitätsklinikum Hamburg Eppendorf, Hamburg
| | - G Salomon
- Martini Klinik, Universitätsklinikum Hamburg Eppendorf, Hamburg
| | - L Budäus
- Universitätsklinikum Hamburg Eppendorf, Martini Klinik, Hamburg
| | - G Adam
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| | - D Beyersdorff
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| |
Collapse
|
27
|
Sauer M, Weinrich J, Salomon G, Tennstedt P, Adam G, Beyersdorff D. Die präoperative Vorhersagegenauigkeit der multiparametrischen Prostata-MRT in der Detektion der Gefäßnervenbündel-Infiltration mithilfe von PI-RADS Version 2. ROFO-FORTSCHR RONTG 2017. [DOI: 10.1055/s-0037-1600470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- M Sauer
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| | - J Weinrich
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| | - G Salomon
- Universitätsklinikum Hamburg Eppendorf, Martini Klinik, Hamburg
| | - P Tennstedt
- Universitätsklinikum Hamburg Eppendorf, Martini Klinik, Hamburg
| | - G Adam
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| | - D Beyersdorff
- Universitätsklinikum Hamburg Eppendorf, Diagnostische und interventionelle Radiologie und Nuklearmedizin, Hamburg
| |
Collapse
|
28
|
|
29
|
|
30
|
Schostak M, Wendler JJ, Baumunk D, Blana A, Ganzer R, Franiel T, Hadaschik B, Henkel T, Köhrmann KU, Köllermann J, Kuru T, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Witzsch U, Liehr UB. Treatment of Small Renal Masses. Urol Oncol 2017. [DOI: 10.1007/978-3-319-42603-7_61-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Salomon G, Ofaiche J, Boulinguez S, Uthurriague C, Meyer N, Tournier E, Abravanel F, Boucher N, Péron JM, Paul C, Livideanu CB. Hépatite E, une cause rare de vascularite cutanée : à propos de 2 cas. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Salomon G, Maza A, Boulinguez S, Paul C, Mazereeuw-Hautier J, Meyer N. Anti-PD1 et xeroderma pigmentosum, une activité sur le mélanome et les carcinomes épidermoïdes. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, George AK, Gupta RT, Kahmann F, Kastner C, Laguna MP, Natarajan S, Rais-Bahrami S, Rastinehad AR, de Reijke TM, Salomon G, Stone N, van Velthoven R, Villani R, Villers A, Walz J, Polascik TJ, de la Rosette JJMCH. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol 2016; 35:695-701. [PMID: 27637908 PMCID: PMC5397427 DOI: 10.1007/s00345-016-1932-1] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Accepted: 09/06/2016] [Indexed: 12/25/2022] Open
Abstract
Purpose To codify the use of multiparametric magnetic resonance imaging (mpMRI) for the interrogation of prostate neoplasia (PCa) in clinical practice and focal therapy (FT). Methods An international collaborative consensus project was undertaken using the Delphi method among experts in the field of PCa. An online questionnaire was presented in three consecutive rounds and modified each round based on the comments provided by the experts. Subsequently, a face-to-face meeting was held to discuss and finalize the consensus results. Results mpMRI should be performed in patients with prior negative biopsies if clinical suspicion remains, but not instead of the PSA test, nor as a stand-alone diagnostic tool or mpMRI-targeted biopsies only. It is not recommended to use a 1.5 Tesla MRI scanner without an endorectal or pelvic phased-array coil. mpMRI should be performed following standard biopsy-based PCa diagnosis in both the planning and follow-up of FT. If a lesion is seen, MRI-TRUS fusion biopsies should be performed for FT planning. Systematic biopsies are still required for FT planning in biopsy-naïve patients and for patients with residual PCa after FT. Standard repeat biopsies should be taken during the follow-up of FT. The final decision to perform FT should be based on histopathology. However, these consensus statements may differ for expert centers versus non-expert centers. Conclusions The mpMRI is an important tool for characterizing and targeting PCa in clinical practice and FT. Standardization of acquisition and reading should be the main priority to guarantee consistent mpMRI quality throughout the urological community. Electronic supplementary material The online version of this article (doi:10.1007/s00345-016-1932-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- M J Scheltema
- Department of Urology, Academic Medical Center, Amsterdam, The Netherlands.
| | - K J Tay
- Department of Surgery, Duke University Medical Center, Durham, NC, USA
| | - A W Postema
- Department of Urology, Academic Medical Center, Amsterdam, The Netherlands
| | - D M de Bruin
- Department of Urology, Academic Medical Center, Amsterdam, The Netherlands.,Department of Biomedical Engineering and Physics, Academic Medical Center, Amsterdam, The Netherlands
| | - J Feller
- Desert Medical Imaging, Indian Wells, CA, USA
| | - J J Futterer
- Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - A K George
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - R T Gupta
- Department of Radiology, Duke University Medical Center, Durham, NC, USA
| | - F Kahmann
- Urologische Praxis Dr. Henkel and Dr. Kahmann, Berlin, Germany
| | - C Kastner
- CamPARI Prostate Cancer Clinic, Cambridge University Hospitals Trust, Cambridge, UK
| | - M P Laguna
- Department of Urology, Academic Medical Center, Amsterdam, The Netherlands
| | - S Natarajan
- Department of Urology, Surgery and Bioengineering, University of California, Los Angeles, CA, USA
| | - S Rais-Bahrami
- Department of Urology and Radiology, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - A R Rastinehad
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - T M de Reijke
- Department of Urology, Academic Medical Center, Amsterdam, The Netherlands
| | - G Salomon
- Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - N Stone
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - R van Velthoven
- Department of Urology, Institut Jules Bordet, Brussels, Belgium
| | - R Villani
- Department of Radiology, North Shore University Hospital, Northwell Health, NY, USA
| | - A Villers
- Department of Urology, Lille University Medical Center, Lille, France
| | - J Walz
- Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France
| | - T J Polascik
- Department of Surgery, Duke University Medical Center, Durham, NC, USA
| | | |
Collapse
|
34
|
Boll M, Hilker TA, Salomon G, Omran A, Nespolo J, Pollet L, Bloch I, Gross C. Spin- and density-resolved microscopy of antiferromagnetic correlations in Fermi-Hubbard chains. Science 2016; 353:1257-60. [DOI: 10.1126/science.aag1635] [Citation(s) in RCA: 242] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 08/18/2016] [Indexed: 11/02/2022]
|
35
|
Affiliation(s)
- G. Salomon
- Institute of Laryngology and Otology, London
| |
Collapse
|
36
|
Wendler JJ, Ganzer R, Hadaschik B, Blana A, Henkel T, Köhrmann KU, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D, Köllermann J, Schostak M, Liehr UB. Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage. World J Urol 2016; 35:11-20. [DOI: 10.1007/s00345-016-1838-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 04/22/2016] [Indexed: 01/05/2023] Open
|
37
|
Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol 2016; 34:1373-82. [PMID: 26892160 PMCID: PMC5026990 DOI: 10.1007/s00345-016-1782-x] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2015] [Accepted: 02/02/2016] [Indexed: 11/12/2022] Open
Abstract
PURPOSE To reach standardized terminology in focal therapy (FT) for prostate cancer (PCa). METHODS A four-stage modified Delphi consensus project was undertaken among a panel of international experts in the field of FT for PCa. Data on terminology in FT was collected from the panel by three rounds of online questionnaires. During a face-to-face meeting on June 21, 2015, attended by 38 experts, all data from the online rounds were reviewed and recommendations for definitions were formulated. RESULTS Consensus was attained on 23 of 27 topics; Targeted FT was defined as a lesion-based treatment strategy, treating all identified significant cancer foci; FT was generically defined as an anatomy-based (zonal) treatment strategy. Treatment failure due to the ablative energy inadequately destroying treated tissue is defined as ablation failure. In targeting failure the energy is not adequately applied to the tumor spatially and selection failure occurs when a patient was wrongfully selected for FT. No definition of biochemical recurrence can be recommended based on the current data. Important definitions for outcome measures are potency (minimum IIEF-5 score of 21), incontinence (new need for pads or leakage) and deterioration in urinary function (increase in IPSS >5 points). No agreement on the best quality of life tool was established, but UCLA-EPIC and EORTC-QLQ-30 were most commonly supported by the experts. A complete overview of statements is presented in the text. CONCLUSION Focal therapy is an emerging field of PCa therapeutics. Standardization of definitions helps to create comparable research results and facilitate clear communication in clinical practice.
Collapse
Affiliation(s)
- A W Postema
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands.
| | - T M De Reijke
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands
| | - O Ukimura
- USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.,Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - W Van den Bos
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands
| | - A R Azzouzi
- Department of Urology, Angers University Hospital, Angers, France
| | - E Barret
- Department of Urology, Institut Montsouris, Université Paris Descartes, Paris, France
| | - D Baumunk
- Department of Urology, Magdeburg University Medical Center, Magdeburg, Germany
| | - A Blana
- Department of Urology, Fuerth Hospital, Fuerth, Germany
| | - A Bossi
- Department of Radiation Oncology, Gustave Roussy Institute, Villejuif, France
| | - M Brausi
- Department of Urology, Ospedale Civile Ramazzini, Carpi, Italy
| | - J A Coleman
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - S Crouzet
- Department of Urology and Transplantation, Edouard Herriot Hospital, Lyon, France
| | - J Dominguez-Escrig
- Department of Urology, Instituto Valenciano de Oncología, Valencia, Spain
| | - S Eggener
- Department of Urology, University of Chicago, Chicago, IL, USA
| | - R Ganzer
- Department of Urology, University of Leipzig, Leipzig, Germany
| | - S Ghai
- Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, Canada
| | - I S Gill
- USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - R T Gupta
- Departments of Radiology, Duke University Medical Center, Durham, NC, USA
| | - T O Henkel
- Urologische Praxis Dr. Henkel & Dr. Kahmann, Berlin, Germany
| | - M Hohenfellner
- Department of Urology, University of Heidelberg, Heidelberg, Germany
| | - J S Jones
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - F Kahmann
- Urologische Praxis Dr. Henkel & Dr. Kahmann, Berlin, Germany
| | - C Kastner
- CamPARI Prostate Cancer Clinic, Cancer Directorate, Cambridge University Hospitals Trust, Cambridge, UK
| | - K U Köhrmann
- Department of Urology, Theresien Krankenhaus Mannheim, Mannheim, Germany
| | - G Kovacs
- Interdisciplinary Brachytherapy Unit, University of Lübeck, Lübeck, Germany
| | - R Miano
- Division of Urology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
| | - R J van Moorselaar
- Department of Urology, Free University Medical Centre, Amsterdam, The Netherlands
| | - N Mottet
- Department of Urology, University Hospital St Etienne, Saint-Étienne, France
| | - L Osorio
- Department of Urology, Porto Hospital Centre, Porto, Portugal
| | - B R Pieters
- Departments of Radiation Oncology, AMC University Hospital, Amsterdam, The Netherlands
| | - T J Polascik
- Departments of Surgery, Duke University Medical Center, Durham, NC, USA
| | - A R Rastinehad
- Department of Urology, Hofstra North Shore-Lij, Hofstra University, Hempstead, NY, USA
| | - G Salomon
- Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - R Sanchez-Salas
- Department of Urology, Institut Montsouris, Université Paris Descartes, Paris, France
| | - M Schostak
- Department of Urology, Magdeburg University Medical Center, Magdeburg, Germany
| | - L Sentker
- Urologische Gemeinschaftspraxis, Sinsheim, Germany
| | - K J Tay
- Departments of Surgery, Duke University Medical Center, Durham, NC, USA
| | - I M Varkarakis
- 2nd Department of Urology, Athens Medical University, University of Athens, Athens, Greece
| | - A Villers
- Department of Urology, Lille University Medical Center, Lille, France
| | - J Walz
- Department of Urology, Institut Paoli-Calmettes, Marseille, France
| | - J J De la Rosette
- Departments of Urology, AMC University Hospital, Amsterdam, The Netherlands
| |
Collapse
|
38
|
Abstract
Accurate identification of the location of carcinoma in the prostate is essential for long-term therapeutic success, in particular for minimally invasive procedures. In recent years many new positive study results for prostate imaging have been reported which must be compared and evaluated and previous conservative assessments may need to be re-evaluated. In addition, combinations of different imaging techniques are increasingly being used in daily clinical routine. Due to technical advancements in sonographic imaging, such as elastography and contrast-enhanced ultrasound (CEUS), the detection rate of prostate cancer can be increased. An overview of the different imaging modalities and current literature are presented in this article.
Collapse
Affiliation(s)
- B Schlenker
- Urologische Klinik und Poliklinik des Klinikums der Universität München, Marchioninistraße 15, 81377, München, Deutschland,
| | | | | |
Collapse
|
39
|
Schiffmann J, Haese A, Leyh-Bannurah SR, Salomon G, Steuber T, Schlomm T, Boehm K, Beyer B, Larcher A, Michl U, Heinzer H, Huland H, Graefen M, Karakiewicz PI. Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy. Eur J Surg Oncol 2015; 41:1547-53. [PMID: 26117216 DOI: 10.1016/j.ejso.2015.05.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Revised: 04/01/2015] [Accepted: 05/19/2015] [Indexed: 10/23/2022] Open
Abstract
PURPOSE Contemporary adherence of the indication to European Association of Urology (EAU) guideline recommendation for pelvic lymph node dissection (PLND) at either open (ORP) or robot-assisted radical prostatectomy (RARP) at a high-volume center is unknown. To assess guideline recommended and observed PLND rates in a high-volume center cohort. METHODS We relied on the Martini-Clinic database and focused on patients treated with either ORP or RARP, between 2010 and 2013. Actual performed PLND was compared to European Association of Urology (EAU) guideline recommendation defined by nomogram predicted risk of lymph node invasion >5%. Categorical and multivariable logistic regression analyses targeted two endpoints: 1) probability of guideline recommended PLND and 2) probability of no PLND, when not recommended by EAU guideline. RESULTS Within 7868 PCa patients, adherence to EAU PLND guideline recommendation was 97.1% at ORP and 96.8% at RARP (p = 0.7). When PLND was not recommended, it was more frequently performed at RARP (71.6%) than at ORP (66.2%) (p = 0.002). Gleason score, PSA and number of positive biopsy cores were independent predictors for both either PLND when recommended, or no PLND when not recommended (all p < 0.05). Clinical tumor stage, age and surgical approach were also independent predictors for no PLND when not recommended (all p < 0.05). CONCLUSIONS Adherence of the indication to EAU guideline recommended PLND is high at this high-volume center. Neither ORP nor RARP represent a barrier for PLND, when recommended. However, a high number of patients underwent PLND despite absence of guideline recommendation. Possible staging advantages and PLND related complications needs to be individually considered, especially, when LNI risk is low.
Collapse
Affiliation(s)
- J Schiffmann
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
| | - A Haese
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - G Salomon
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Steuber
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Schlomm
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Boehm
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
| | - B Beyer
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Larcher
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy
| | - U Michl
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Heinzer
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Huland
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Graefen
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada
| |
Collapse
|
40
|
Schostak M, Köllermann J, Hadaschik B, Blana A, Ganzer R, Henkel T, Köhrmann K, Liehr UB, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D. [Cancer control in focus insights and future perspectives for the focal treatment of prostate cancer]. Aktuelle Urol 2015; 46:39-44. [PMID: 25658230 DOI: 10.1055/s-0034-1396803] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Faced with the dilemma of choosing between the extremes of standard whole gland therapy and active surveillance, those affected by prostate cancer have recently been on the lookout for less invasive alternatives. Particularly the question of whether it would be possible in low risk cancer to treat only the tumour itself while sparing the organ has long been considered. This article discusses the pros and cons of focal treatment and elucidates the latest innovative technologies. High overtreatment rates in low-risk patients submitted to standard therapy and considerable technological advances in diagnosis (particularly multiparametric MRI) and therapy are regarded by the authors as key arguments for abandoning complete tumour eradication with its side effects in favour of sufficient local cancer control by focal treatment with better preserved quality of life in suitable cases.
Collapse
Affiliation(s)
- M. Schostak
- Klinik für Urologie und Kinderurologie, Universitätsklinikum Magdeburg
| | - J. Köllermann
- MVZ Hanse Histologikum, Schwerpunkt Uropathologie, Hamburg
| | - B. Hadaschik
- Urologische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg
| | - A. Blana
- Klinik für Urologie und Kinderurologie, Klinikum Fürth
| | - R. Ganzer
- Urologische Klinik und Poliklinik der Universität Leipzig
| | - T. Henkel
- Urologische Praxis Dr. Henkel & Dr. Kahmann, Berlin
| | - K. Köhrmann
- Klinik für Urologie, Theresienkrankenhaus Mannheim
| | - U.-B. Liehr
- Klinik für Urologie und Kinderurologie, Universitätsklinikum Magdeburg
| | - S. Machtens
- Klinik für Urologie, Marienkrankenhaus Bergisch-Gladbach
| | - A. Roosen
- Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Klinikum Großhadern, München
| | | | - L. Sentker
- Urologische Gemeinschaftspraxis, Sinsheim
| | - U. Witzsch
- Klinik für Urologie und Kinderurologie, Krankenhaus Nordwest, Frankfurt/Main
| | - H.-P. Schlemmer
- Abteilung für Radiologie des Deutschen Krebsforschungszentrums Heidelberg
| | - D. Baumunk
- Klinik für Urologie und Kinderurologie, Universitätsklinikum Magdeburg
| |
Collapse
|
41
|
Roosen A, Ganzer R, Hadaschik B, Köllermann J, Blana A, Henkel T, Liehr UB, Baumunk D, Machtens S, Salomon G, Sentker L, Witsch U, Köhrmann K, Schostak M. Erratum zu: Fokale Therapie des Prostatakarzinoms in Deutschland – Status 2014. Urologe A 2014. [DOI: 10.1007/s00120-014-3591-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Boehm K, Beyer B, Tennstedt P, Schiffmann J, Budaeus L, Haese A, Graefen M, Schlomm T, Heinzer H, Salomon G. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer. World J Urol 2014; 33:801-6. [DOI: 10.1007/s00345-014-1351-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2014] [Accepted: 06/19/2014] [Indexed: 10/25/2022] Open
|
43
|
Roosen A, Ganzer R, Hadaschik B, Köllermann J, Blana A, Henkel T, Liehr AB, Baumunk D, Machtens S, Salomon G, Sentker L, Witsch U, Köhrmann K, Schostak M. Fokale Therapie des Prostatakarzinoms in Deutschland – Status 2014. Urologe A 2014; 53:1040-5. [DOI: 10.1007/s00120-014-3532-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Schiffmann J, Tennstedt P, Fischer J, Tian Z, Beyer B, Boehm K, Sun M, Gandaglia G, Michl U, Graefen M, Salomon G. Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate. World J Urol 2014; 32:925-30. [PMID: 24871425 DOI: 10.1007/s00345-014-1330-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Accepted: 05/19/2014] [Indexed: 11/30/2022] Open
Abstract
PURPOSE The role of HistoScanning™ (HS) in prostate biopsy is still indeterminate. Existing literature is sparse and controversial. To provide more evidence according to that important clinical topic, we analyzed institutional data from the Martini-Clinic, Prostate Cancer Center, Hamburg. METHODS Patients who received prostate biopsy and who also received HS were included in the study cohort. A single examiner, blinded to pathological results, re-analyzed all HS data in accordance with sextants of the prostate. Each sextant was considered as an individual case. Corresponding results from biopsy and HS were analyzed. The area under the receiver-operating characteristic curve (AUC) for the prediction of a positive biopsy by HS was calculated. Furthermore, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were assessed according to different HS signal volume cutoffs (>0, >0.2 and >0.5 ml). RESULTS Overall, 198 men were identified and 1,188 sextants were analyzed. The AUC to predict positive biopsy results by HS was 0.58. Sensitivity, specificity, PPV and NPV for HS to predict positive biopsy results per sextant, depending on different HS signal volume cutoffs (>0, >0.2 and >0.5 ml) were 84.1, 27.7, 29.5 and 82.9 %, 60.9, 50.6, 28.8 and 79.7 %, and 40.1, 73.3, 33.1 and 78.8 %, respectively. CONCLUSIONS Positive HS signals do not accurately predict positive prostate biopsy results according to sextant analysis. We cannot recommend a variation of well-established random biopsy patterns or reduction of biopsy cores in accordance with HS signals at the moment.
Collapse
Affiliation(s)
- J Schiffmann
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
Recently several new technologies for prostate imaging have been developed. The aim of these technologies was to improve the diagnosis of prostate cancer. Especially the transrectal ultrasound (TRUS) has been refined to the so-called enhanced ultrasound, as regular grey scale TRUS has limited ability to identify cancer lesions in the prostate. In several studies elastography has shown good capability to identify cancer lesions in the prostate as well as to absolutely increase the detection rate of randomized biopsies by up to 10 %.. Contrast-enhanced ultrasound shows varying results in the published literature with increased detection rates on the one hand and unchanged detection rates relative to randomized biopsy on the other hand. The online available ANNA/C-TRUS system shows detection rates with six targeted biopsies that are comparable to the published detection rates of randomized saturation biopsies. Direct systematic comparison to randomized biopsies is missing. The Histoscanning system currently provides the poorest data as no biopsy studies are available. Multicenter trials are mandatory for all new imaging technologies in order to implement them as standard into clinical practice.
Collapse
Affiliation(s)
- J Walz
- Department of Urology, Institut Paoli-Calmettes Cancer Centre, 232, Boulevard Ste. Marguerite/ B.P.: 156, F-13273 Marseille, Frankreich.
| | | | | | | |
Collapse
|
46
|
Regier M, Seiwerts C, Leyh-Bannurah S, Salomon G, Steuber T, Heinzer H, Haese A, Graefen M, Laqmani A, Adam G, Budäus L. Identifikation eines Schwellenwertes des Apparenten-Diffusionskoeffizienten (ADC) in der Diffusionsgewichteten MRT (DWI) zur Beurteilung pelviner Lymphknoten (LK) bei histologisch gesichertem Prostata. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Baumunk D, Blana A, Ganzer R, Henkel T, Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch U, Köhrmann K, Schostak M. Fokale Therapie des Prostatakarzinoms. Urologe A 2012; 52:549-56. [DOI: 10.1007/s00120-012-3002-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Salomon G, Budaeus L. 799 Subjective risk assessment for the diagnosis of prostate cancer using real time elastography (RTE) prior to biopsy and assessment of real time elastography for prostate cancer detection by comparing RTE based and grey scale ultrasound biopsies. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/s1569-9056(12)60796-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
49
|
Budäus L, Isbarn H, Schriefer P, Chun F, Fisch M, Steuber T, Salomon G, Huland H, Heinzer H, Graefen M. MP-13.01 Radical Prostatectomy in Men with Continued Oral Aspirin Medication: Revisiting an Old Paradigm? Urology 2011. [DOI: 10.1016/j.urology.2011.07.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
50
|
Budäus L, Isbarn H, Chun F, Ahyai S, Dahlem R, Fisch M, Salomon G, Huland H, Heinzer H, Graefen M. POD-03.01 Risk Assessment for Prostate Cancer Metastases by Using the Capra Score: Results from 3239 European Patients. Urology 2011. [DOI: 10.1016/j.urology.2011.07.412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|